AlphaMadera's AlphaVal page computes ADMA Biologics, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag ADMA as undervalued, fairly valued, or overvalued.

What is ADMA Biologics, Inc.'s fair value?

Fair value for ADMA is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value ADMA?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from ADMA's most recent reported fundamentals.

ADMA - ADMA Biologics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $21.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 85% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Overvalued Moderate

Trading 31.9% above fair value

Current Price $8.24

Bear Case $3.47 57.9% downside ($3.47 - $8.24) / $8.24 = -57.9% 12% stage 1 growth, 11% discount

Fair Value $6.25 24.2% downside ($6.25 - $8.24) / $8.24 = -24.2% 20% stage 1 growth, 11% discount

Bull Case $9.74 18.2% upside ($9.74 - $8.24) / $8.24 = 18.2% 26% stage 1 growth, 11% discount

Adjust Assumptions

DCF Stage 1 Growth Rate

20.0%

Discount Rate (WACC)

11.0%

Terminal Growth Rate

3.0%

Key Value Driver

FCF growth rate (20% base case)

Terminal Value % of EV 46%

Implied Market Multiple 148.6x

Plain-Language Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $21.00 from 10 analysts, using a 20% weight on analyst consensus. That produces an estimated intrinsic value of $6.25 per share.

Warnings

ℹ Wall Street's average price target is $21.00 (from 10 analysts). Our estimate is 88% below the consensus -- consider that gap carefully.

Key Risks

P/E alone misleads — earnings depressed by growth investment
Cyclical or commodity businesses may be misclassified as platforms
Terminal value dominance suggests sensitivity to long-run assumptions